BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.

Revenue
+33.8%
EPS
+143.7%
Free cash flow
+33.6%
Total debt
+491.3%

Quarter to September 2026, against a year earlier

409.87 22.62 +5.84%
Market cap
$40.4B
P/E
65.9×
Fwd P/E
48.8×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a

BeOne Medicines Ltd. - Sponsored ADR 8-K filed Aug 7, 2024

Period ended Aug 7, 2024 · Filed · accepted 6:04 AM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov